EZH2 inhibitors enhance effectiveness of cancer immunotherapies

Drugs News

EZH2 inhibitors enhance effectiveness of cancer immunotherapies
AntibodyBispecific AntibodyCancer
  • 📰 NewsMedical
  • ⏱ Reading Time:
  • 46 sec. here
  • 16 min. at publisher
  • 📊 Quality Score:
  • News: 71%
  • Publisher: 71%

An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, according to a preclinical study led by Weill Cornell Medicine lymphoma researchers.

Weill Cornell Medicine Dec 5 2024

Dr. Wendy Béguelin, senior author, John P. Leonard, MD/Gwirtzman Family Research Scholar in Lymphoma and an assistant professor of pharmacology in medicine at Weill Cornell Medicine This study proposed that inhibiting EZH2 might help enhance the potency and durability of these immunotherapies. EZH2 is an enzyme that normally helps program cell behavior by controlling the expression of specific genes. Mutations in the EZH2 gene, which makes the enzyme more active, are now recognized as common features of lymphomas, and inhibiting this enzyme has been found to benefit lymphoma patients even when they have non-mutant EZH2.

Suitable preclinical animal models to test this hypothesis have not been available, so Dr. Béguelin and her colleagues started by developing a new mouse model for follicular lymphoma and a tumor line for the more common and aggressive diffuse large B-cell lymphoma.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

NewsMedical /  🏆 19. in UK

Antibody Bispecific Antibody Cancer Cell Enzyme Follicular Lymphoma Immunotherapy Lymph Node Lymphoma Medicine Preclinical Research T-Cell Tumor

United Kingdom Latest News, United Kingdom Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

EZH2 enzyme drives aggressive tumor growth in treatment-resistant prostate cancerEZH2 enzyme drives aggressive tumor growth in treatment-resistant prostate cancerAn enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study by scientists at Weill Cornell Medicine.
Read more »

Fungus found in the mouse stomach may hold a key to fungal evolution in the gutFungus found in the mouse stomach may hold a key to fungal evolution in the gutA fungus discovered in the mouse stomach may hold a key to fungal evolution within the gastrointestinal tract, according to new research led by Weill Cornell Medicine investigators.
Read more »

Psychological stress and pain contribute to cardiovascular disease in asylum seekersPsychological stress and pain contribute to cardiovascular disease in asylum seekersMany individuals seeking asylum in the United States show increased stress and pain symptoms that are associated with indications of cardiovascular disease according to Weill Cornell Medicine researchers.
Read more »

Study reveals how brainstem neurons control eye movementsStudy reveals how brainstem neurons control eye movementsWorking with week-old zebrafish larva, researchers at Weill Cornell Medicine and colleagues decoded how the connections formed by a network of neurons in the brainstem guide the fishes' gaze.
Read more »

Study reveals the secret to cellular youth may lie in nucleolus sizeStudy reveals the secret to cellular youth may lie in nucleolus sizeThe secret to cellular youth may depend on keeping the nucleolus—a condensed structure inside the nucleus of a cell—small, according to Weill Cornell Medicine investigators.
Read more »

Virtual screening yields small molecules to enhance cancer immunotherapyVirtual screening yields small molecules to enhance cancer immunotherapyThe process of identifying promising small molecule drug candidates that target cancer checkpoints may become faster and smarter through virtual screening, according to Weill Cornell Medicine researchers.
Read more »



Render Time: 2025-02-16 07:00:31